Joslin and Johnson & Johnson Announce New Partnership to Improve Diabetes Management in China Hospitals
BOSTON – (March 5, 2015) – Joslin Diabetes Center announced today that they have entered into a partnership with Johnson and Johnson Medical (Shanghai) Co. Ltd (hereafter, JJMS) to improve glycemic control for people with diabetes who are hospitalized in Chinese hospitals. The aim of this alliance is to utilize Joslin’s expertise in diabetes management to elevate the quality of diabetes care in China.
“Joslin is honored to share its expertise in partnership with JJMS to achieve our common commitment to improve health for people with diabetes in China,” said William C. Hsu, MD, Vice President for International Programs at Joslin and Assistant Professor at Harvard Medical School. “We are confident that people living with diabetes in China will benefit greatly from our alliance, particularly from new approaches to comprehensive, team-based care and implementing protocols for managing blood glucose during hospital stays.”
Joslin and JJMS will collaborate on a program to improve glucose management for diabetes patients in selected hospitals and to help Chinese providers adopt a multidisciplinary team-based approach for diabetes care. To implement these changes, Joslin and JJMS will educate health care providers and administrators in China about inpatient glucose management (IPGM) and the benefits of team care, train providers in pilot hospitals on how to execute specific protocols for glucose management in their patients, and lastly, measure outcomes to help Chinese hospitals measure their progress.
In the U.S. and at Joslin’s associated hospitals, these practices have proved to be successful at decreasing the length of hospital stays for patients with diabetes, as well as reducing the rates of infections and readmissions.
Shi Chun, Business Unit Director for JJMS Lifescan, commented on the J&J-Joslin collaboration: “Based on the J&J Credo, creating value through innovation is one of our core business drivers. We will focus on bringing improved glucose management technologies and solutions to Chinese diabetes patients and healthcare providers. Together with Joslin, we are hoping to help advance diabetes care in China.”
In 2010, there were an estimated 114 million people in China with diabetes, making China the country with the world’s largest diabetes population. As a recognized leader in diabetes care, especially among Asian populations in the U.S., Joslin hopes to positively impact the high rates of diabetes and prediabetes in China.